Elicio Therapeutics (ELTX) Other Gross PP&E Adjustments (2020 - 2026)
Elicio Therapeutics posted quarterly Other Gross PP&E Adjustments of -$3.1 million for Q1 2026, up 25.68% year-on-year from -$2.5 million in Q1 2025, and up 12.34% on a QoQ basis from -$3.5 million in Q4 2025.
Elicio Therapeutics (ELTX) has 7 years of Other Gross PP&E Adjustments data on file, last reported at -$3.1 million in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 25.68% year-over-year to -$3.1 million; the trailing twelve-month figure through Mar 2026 stood at -$3.1 million (up 25.68% YoY), and the FY2025 full-year result was -$3.5 million, up 26.64% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at -$3.1 million, up from -$3.5 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$126000.0 in Q1 2023 and bottomed at -$5.6 million in Q4 2023.
- The 5-year median for Other Gross PP&E Adjustments is -$4.2 million (2025), against an average of -$4.0 million.
- The widest annual swing landed in 2023, when Other Gross PP&E Adjustments soared 95.54%; it then slumped 4163.49% in 2024.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at -$5.3 million in 2022, then retreated by 5.7% to -$5.6 million in 2023, then climbed by 12.99% to -$4.8 million in 2024, then advanced by 26.64% to -$3.5 million in 2025, then rose by 12.34% to -$3.1 million in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$3.1 million (Q1 2026), -$3.5 million (Q4 2025), and -$3.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Elicio Therapeutics | 217.63 Mn | 202.68 Mn | - | -3.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.11 Mn |
| Mar 31, 2026 | -3.11 Mn |
| Dec 31, 2025 | -3.55 Mn |
| Dec 31, 2025 | -3.55 Mn |
| Sep 30, 2025 | -3.75 Mn |
| Sep 30, 2025 | -3.75 Mn |
| Jun 30, 2025 | -3.85 Mn |
| Jun 30, 2025 | -3.85 Mn |
| Mar 31, 2025 | -4.19 Mn |
| Mar 31, 2025 | -4.19 Mn |
| Dec 31, 2024 | -4.84 Mn |
| Dec 31, 2024 | -4.84 Mn |
| Sep 30, 2024 | -4.91 Mn |
| Sep 30, 2024 | -4.91 Mn |
| Jun 30, 2024 | -4.96 Mn |
| Jun 30, 2024 | -4.96 Mn |
| Mar 31, 2024 | -5.37 Mn |
| Mar 31, 2024 | -5.37 Mn |
| Dec 31, 2023 | -5.56 Mn |
| Dec 31, 2023 | -5.56 Mn |
| Sep 30, 2023 | -5.54 Mn |
| Sep 30, 2023 | -5.54 Mn |
| Jun 30, 2023 | -5.52 Mn |
| Jun 30, 2023 | -5.52 Mn |
| Mar 31, 2023 | -126,000.00 |
| Mar 31, 2023 | -126,000.00 |
| Dec 31, 2022 | -5.26 Mn |
| Dec 31, 2022 | -5.26 Mn |
| Sep 30, 2022 | -2.42 Mn |
| Sep 30, 2022 | -2.42 Mn |
| Jun 30, 2022 | -2.62 Mn |
| Jun 30, 2022 | -2.62 Mn |
| Mar 31, 2022 | -2.82 Mn |
| Mar 31, 2022 | -2.82 Mn |
| Dec 31, 2021 | -6.09 Mn |
| Dec 31, 2021 | -6.09 Mn |
| Sep 30, 2021 | -3.22 Mn |
| Sep 30, 2021 | -3.22 Mn |
| Jun 30, 2021 | -3.50 Mn |
| Jun 30, 2021 | -3.50 Mn |
| Mar 31, 2021 | -3.86 Mn |
| Mar 31, 2021 | -3.86 Mn |
| Dec 31, 2020 | -4.81 Mn |
| Dec 31, 2020 | -4.81 Mn |